www.nikangtx.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $260.25MM
NiKang Therapeutics is a biotech company focused on discovering and developing innovative small molecules oncology medicines to help patients with unmet medical needs. The company's strategy enables discovery and advancement of proprietary drug candidates with the most desirable pharmacological features into clinical studies.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/26/2021 | Series C | $200MM | $xx.xx | $475.12MM | Ally Bridge Group, Blackrock, Casdin Capital, Cbc Group, Cormorant Asset Management, Ecor1 Capital, Hbm Healthcare Investments, Invus, Janus Henderson Investors, Lilly Asia Ventures, Logos Capital, Matrix Partners China, Octagon Capital Advisors, Pavillion Capital, Perceptive Advisors, Pfm Health Sciences, Ra Capital Management, Rtw Investments, Samsara Biocapital, Surveyor Capital, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
34,854,728
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ally Bridge Group, Blackrock, Casdin Capital, Cbc Group, Cormorant Asset Management, Ecor1 Capital, Hbm Healthcare Investments, Invus, Janus Henderson Investors, Lilly Asia Ventures, Logos Capital, Matrix Partners China, Octagon Capital Advisors, Pavillion Capital, Perceptive Advisors, Pfm Health Sciences, Ra Capital Management, Rtw Investments, Samsara Biocapital, Surveyor Capital, Wellington Management
|
||||||
09/14/2020 | Series B2 | $5.25MM | $xx.xx | $112.62MM | Casdin Capital, Cbc Group, Hbm Healthcare Investments, Lilly Asia Ventures, Matrix Partners China, Octagon Investments, Rtw Investments | |
Price per Share
$xx.xx
Shares Outstanding
2,083,894
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Casdin Capital, Cbc Group, Hbm Healthcare Investments, Lilly Asia Ventures, Matrix Partners China, Octagon Investments, Rtw Investments
|
||||||
09/14/2020 | Series B1 | $45MM | $xx.xx | $112.62MM | Casdin Capital, Cbc Group, Hbm Healthcare Investments, Lilly Asia Ventures, Matrix Partners China, Octagon Investments, Rtw Investments | |
Price per Share
$xx.xx
Shares Outstanding
16,071,426
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Casdin Capital, Cbc Group, Hbm Healthcare Investments, Lilly Asia Ventures, Matrix Partners China, Octagon Investments, Rtw Investments
|
||||||
07/28/2017 | Series A | $10MM | $xx.xx | $15.38MM | Cbc Group | |
Price per Share
$xx.xx
Shares Outstanding
10,000,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Cbc Group
|